EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Lundbeck terminated development of Lu AF35700 in the wake of the failure of the drug in patients with schizophrenia. Release 

> Analysts at Jefferies raised their price target for Genmab after reviewing the prospects of its pipeline programs. Genmab reported first-half results this week. Statement 

> The Dementia Discovery Fund invested £6.5 million ($7.9 million) in AstronauTx, a startup that aims to treat Alzheimer’s disease by targeting astrocytes. Release 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> AC Immune entered into a neurodegenerative disease research collaboration with the University of Pennsylvania. Statement 

> Scotland’s Synpromics accepted a takeover offer from AskBio. Release 

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.